Pegenzileukin not checked
Sanofi · THOR-707 · SAR444245
FollowEvery change as it happens, and a Monday email
Trials
1 active
8 in total · 3 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Pharmaceutical form: Solution for infusion; Route of administration: Intravenous”In the company’s words, NCT04643002 on ClinicalTrials.gov
- Tested for
- Plasma Cell Myeloma Refractory
- Main trialPhase 1/2
- “The purpose of this umbrella study is to evaluate isatuximab when combined with novel agents with or without dexamethasone in participants with relapsed or refractory myeloma. Substudy 01 is the control Substudy. Substudies 02, 03, and 06 are controlled experimental substudies. Substudies 04 and 05 are independent experimental substudies.”In the company’s words, NCT04643002 on ClinicalTrials.gov
- Other names
- THOR-707 · SAR444245
Other drugs for Plasma Cell Myeloma Refractory
- MezigdomideCelgene · Phase 3
- Anitocabtagene-autoleucelGilead (Kite) · Phase 3
- CM336Keymed Biosciences Co.Ltd · Phase 3
- IBI3003Innovent · Phase 3
- PomalidomideCelgene · Phase 3
- CevostamabRoche · Phase 3
Coming up1
- 13 Sep 2027Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials8
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | 13 Sep 2027 | Isatuximab in Combination With Novel Agents in RRMM - Master Protocol | |
| Phase 2Terminated | 18 Jul 2023 | A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202) | |
| Phase 2Terminated | 21 Jul 2023 | A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With HNSCC (Master Protocol) (Pegathor Head and Neck 204) | |
| Phase 2Completed | 26 Jul 2023 | A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203) | |
| Phase 2Terminated | 14 Sep 2023 | A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) [Pegathor Lymphoma 205] | |
| Phase 1/2Terminated | 22 Aug 2023 | A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201) | |
| Phase 1/2Terminated | 2 Dec 2025 | A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors (THOR-707-101) | |
| Phase 1/2Ended | not given | Phase 1/2 trial evaluating isatuximab in combination with pegenzileukin in relapsed or refractory multiple myeloma (RRMM) previously exposed to anti-CD38 and anti-BCMA |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026